Botox maker AbbVie raises profit forecast after strong sales of immunology drugs

AbbVie has a significant presence in Ireland, in Dublin, Sligo, in Carrigtwohill in Co Cork

AbbVie, the makers of Botox, raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq.

AbbVie, the makers of Botox, raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq.

AbbVie's forecast raise comes on the back of the European Union's framework trade deal with the United States, under which all EU-produced pharmaceuticals entering the US will be subject to a 15% tariff.